These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17786984)

  • 21. Medium-throughput hydrate screening using the Crystal 16™.
    Sistla A; Wu Y; Khamphavong P; Liu J
    Pharm Dev Technol; 2011 Apr; 16(2):102-9. PubMed ID: 20088649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of a rational vs. high throughput approach for rapid salt screening and selection.
    Collman BM; Miller JM; Seadeek C; Stambek JA; Blackburn AC
    Drug Dev Ind Pharm; 2013 Jan; 39(1):29-38. PubMed ID: 22380522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved group contribution parameter set for the application of solubility parameters to melt extrusion.
    Just S; Sievert F; Thommes M; Breitkreutz J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1191-9. PubMed ID: 23628829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New prediction methods for solubility parameters based on molecular sigma profiles using pharmaceutical materials.
    Niederquell A; Wyttenbach N; Kuentz M
    Int J Pharm; 2018 Jul; 546(1-2):137-144. PubMed ID: 29772285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of aqueous solubility of drugs and pesticides with COSMO-RS.
    Klamt A; Eckert F; Hornig M; Beck ME; Bürger T
    J Comput Chem; 2002 Jan; 23(2):275-81. PubMed ID: 11924739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solubility of chiral species as function of the enantiomeric excess.
    Coquerel G
    J Pharm Pharmacol; 2015 Jun; 67(6):869-78. PubMed ID: 25918978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calorimetric investigation of solvent-mediated transformation of sulfamerazine polymorphism.
    Kawakami K; Asami Y; Takenoshita I
    J Pharm Sci; 2010 Jan; 99(1):76-81. PubMed ID: 19718749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
    Hsieh DS; Sarsfield BA; Davidovich M; DiMemmo LM; Chang SY; Kiang S
    J Pharm Sci; 2010 Sep; 99(9):4096-105. PubMed ID: 20564337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new expanded solubility parameter approach.
    Stefanis E; Panayiotou C
    Int J Pharm; 2012 Apr; 426(1-2):29-43. PubMed ID: 22260970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model evaluation for the prediction of solubility of active pharmaceutical ingredients (APIs) to guide solid-liquid separator design.
    Moodley K; Rarey J; Ramjugernath D
    Asian J Pharm Sci; 2018 May; 13(3):265-278. PubMed ID: 32104400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media.
    Bard B; Martel S; Carrupt PA
    Eur J Pharm Sci; 2008 Mar; 33(3):230-40. PubMed ID: 18207706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applications of process analytical technology to crystallization processes.
    Yu LX; Lionberger RA; Raw AS; D'Costa R; Wu H; Hussain AS
    Adv Drug Deliv Rev; 2004 Feb; 56(3):349-69. PubMed ID: 14962586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From Quantum Chemistry to Prediction of Drug Solubility in Glycerides.
    Alsenz J; Kuentz M
    Mol Pharm; 2019 Nov; 16(11):4661-4669. PubMed ID: 31518142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of predictive models for stable solid solution formation.
    Albers J; Matthée K; Knop K; Kleinebudde P
    J Pharm Sci; 2011 Feb; 100(2):667-80. PubMed ID: 20803574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling the phase behavior in mixtures of pharmaceuticals with liquid or supercritical solvents.
    Tsivintzelis I; Economou IG; Kontogeorgis GM
    J Phys Chem B; 2009 May; 113(18):6446-58. PubMed ID: 19368360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling, solubility and pK(a) of five sparingly soluble drugs.
    Domańska U; Pobudkowska A; Pelczarska A; Zukowski L
    Int J Pharm; 2011 Jan; 403(1-2):115-22. PubMed ID: 21034801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process.
    Chun NH; Wang IC; Lee MJ; Jung YT; Lee S; Kim WS; Choi GJ
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):854-61. PubMed ID: 23454054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of the cosolvency models for predicting solubility in solvent mixtures: An update.
    Jouyban A
    J Pharm Pharm Sci; 2019; 22(1):466-485. PubMed ID: 31545702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks.
    Saal C; Petereit AC
    Eur J Pharm Sci; 2012 Oct; 47(3):589-95. PubMed ID: 22885099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.